This analysis focuses on emerging pharmacological and non-pharmacological strategies in the treatment of obesity, as well as evolving new paradigms for the future. It describes the contribution of incretin-based therapies, particularly Glucagon-like peptide-1 (GLP-1) receptor agonists and their multi-agonist counterparts, which provide robust effects on weight loss and metabolic outcomes. In addition, the study describes an accelerated and assorted pipeline of drugs that are not GLP-1 based, demonstrating new delivery options and a rapidly evolving digital health component of personalized care.

• What impact will the significant spending by pharmaceutical giants, the emergence of online health platforms, and the increasing customer demand for personalized interventions have on future growth potential?
• Which growth avenues are emerging in GLP-1-based multi-agonists, advanced delivery formats, and integration with digital health and personalized care?
• How can you assess the strategic direction of major companies and the aggressive timelines presented by regulators to optimize your growth strategies?